Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a global developer, manufacturer, and marketer of technologies, products, and services designed to advance life science applications. The company's core business supports research, pharmaceutical and therapy discovery, bioproduction, and preclinical testing for pharmaceutical and therapy development. Headquartered in Holliston, Massachusetts, United States, Harvard Bioscience aims to be a trusted partner in discovery, production, and safety and regulatory compliance for its global customer base.

The company offers a wide array of products for life science research, organized into two primary categories: Cellular and Molecular Technologies (CMT) and Preclinical product families. CMT products include syringe and peristaltic infusion pumps, electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and equipment for molecular and cellular analysis, marketed under brands such as Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, Multi Channel Systems, and Warner. The Preclinical product family provides platforms for assessing physiological data from organisms for research and drug development, featuring implantable and externally worn telemetry systems, behavioral products, and isolated organ and surgical instruments under brands like DSI, Panlab, Hugo Sachs, and Buxco. Harvard Bioscience also provides comprehensive services including installation, training, hardware maintenance, technical support, and scientific guidance. Their products and services cater to academic institutions, government laboratories, pharmaceutical and biotechnology companies, and contract research organizations worldwide.

In recent leadership changes, John Duke was appointed President and Chief Executive Officer, effective July 28, 2025, succeeding Jim Green. Mark Frost serves as the Chief Financial Officer and Treasurer. The company has been active in strategic initiatives, including a debt refinancing in December 2025, which secured a $40.0 million credit facility. Furthermore, in January 2026, Harvard Bioscience announced a strategic consolidation of its manufacturing operations, involving the phased closure of its Holliston, MA plant, to enhance efficiency and support long-term growth.